Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm

Similar documents
Cho et al., 2009 Journal of Cardiology (2009), 54:

Supplement materials:

Estrogens vs Testosterone for cardiovascular health and longevity

Acetylcholine coronary spasm provocation testing: Revaluation in the real clinical practice

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

LXIV: DRUGS: 4. RAS BLOCKADE

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan

Supplementary Appendix

egfr > 50 (n = 13,916)

Tables of Normal Values (As of February 2005)

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Aspirin Resistance in Patients with Chronic Renal Failure (P 5325)

Cardiac Pathophysiology

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016

AGING KIDNEY IN HIV DISEASE

A case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY

Supplementary Appendix

Correlation of novel cardiac marker

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

Jared Moore, MD, FACP

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Serotonin Receptor Blockade Effective for Postprandial Vasospastic Angina Associated With Dumping Syndrome After Esophagectomy:

Disclosure Information : No conflict of interest

Patient is healthy with no chronic disease or significant risk factors [16%].

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

UTHEALTH HOUSTON CCTS BIOBANK VARIABLE LIST

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009

Supplementary Online Content

Classification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy

Supplementary Online Content

Aldosterone Antagonism in Heart Failure: Now for all Patients?

HFpEF, Mito or Realidad?

Cardiovascular disease and diabetes Vascular harmony


Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

300 Biomed Environ Sci, 2018; 31(4):

ijcrr A DIFFUSE CORONARY SPASM A VARIANT OF A VARIANT?

Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI

Clinical Practice Guideline

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Aldosterone synthase inhibitors. John McMurray BHF Cardiovascular Research Centre University of Glasgow

coronary spasm (CS). Interactions between hemoglobin and high-sensitivity C-reactive protein (hs-crp) in patients with CS have not been

Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

IN-HF on line: patient settings (Enrollement period= )

Drugs acting on the reninangiotensin-aldosterone

Diabetes and Hypertension

Hypertension Management in Diabetic Patients

REGULATION OF CARDIOVASCULAR SYSTEM

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010

DECLARATION OF CONFLICT OF INTEREST

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Structure and organization of blood vessels

Decrease in Plasma Adiponectin Concentrations in Patients With Variant Angina Pectoris

Real World Experience with Renal Denervation Therapy

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

The Study of Endothelial Function in CKD and ESRD

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Rikshospitalet, University of Oslo

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Supplementary Note Details of the patient populations studied Strengths and weakness of the study

THE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS

International Journal of Health Sciences and Research ISSN:

CVD Prevention, Who to Consider

Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to

The Impact of Smoking on Acute Ischemic Stroke

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

HYPERTENSIVE VASCULAR DISEASE

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL

Cardiorenal Syndrome

The Author(s) This article is published with open access by ASEAN Federation of Cardiology

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Cardiovascular Pharmacotherapy

Using the New Hypertension Guidelines

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

Low HDL-levels: leave it or treat it?

Importance of the Spasm Provocation Test in Diagnosing and Clarifying the Activity of Vasospastic Angina

SMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR

Condition/Procedure Measure Compliance Criteria Reference Attribution Method

Ischemic heart disease

SUPPLEMENTAL MATERIAL

Investigating the Frequency of Atherosclerosis Risk Factors in Patients Suffering from X Syndrome

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Assessment of vitamin D levels in patients with acute coronary syndrome

Antialdosterone treatment in heart failure

M2 TEACHING UNDERSTANDING PHARMACOLOGY

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

Transcription:

Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm Department of Cardiology Keiji Inoue Akira Ueoka, Naoki Maruyama, Yoshiaki Shimoda, Eigo Kishita, Yoshinori Tsubakimoto, Tomohiko Sakatani, Akiko Matsuo, Hiroshi Fujita, Makoto Kitamura

Background 1 1. Coronary spasm has been shown to play an important role in the pathogenesis of not only vasospastic angina but also ischemic heart disease including angina pectoris, myocardial infarction and sudden death. 2. Despite a large number of experimental and clinical investigations, the precise pathophysiology and mechanisms of vasospasm remains unknown.

Background 2 1. Patients with coronary spasm may have endothelial cell dysfunction lead by oxidative stress. 2. Impaired reactivity of vascular smooth muscle has been reported as a chief mechanism of vasospasm. 3. Chronic low-grade inflammation seems to be associated with the pathogenesis of coronary spasm. 4. The renin-angiotensin-aldosterone system (RAAS) may cause both endothelial dysfunction and hypercontraction of coronary smooth muscle cell. 5. The aldosterone has the potential to increase vascular inflammatory reaction.

Circulation. 23;18:24-246.

Circulation. 27;116:2435-2443.

Control Aldosterone Kidney International. 25;67:168-1682

Am J Physiol Heart Circ Physiol. 22;283:182-181.

Hypothesis The elevated aldostrone, final mediator of RAAS, is supposed to induce vascular inflammatory injury followed by vasospasm. Aim We elucidated the role of the aldosterone and inflammation in coronary vasospasm patients.

Methods 1 1. Consecutive 48 patients without organic coronary lesion (213 men, 195 women, age 67.4±12.6) were studied. 2. After diagnostic coronary angiography spasm provocation test was performed using ergonovine maleate. 3. Patients with proven coronary vasospasm (> 9% vessel diameter reduction during selective intracoronary ergonovine maleate as compared with the diameter following intracoronary nitroglycerin) but without coronary stenosis were diagnosed as vasospasm angina. 4. Patients without vasospasm and organic coronary lesion were diagnosed as non-spasm disease.

Methods 2 1. According to the results of the provocation test, the subjects were divided into two groups: the Spasm group of 144 patients and the Non-spasm group of 264 patients. 2. The levels of aldosterone and C-reactive protein (CRP) measured immediately before angiography were examined. Clinical data including aldosterone and CRP and other coronary risk factors were compared between 2 groups. 3. Exclusion criteria acute coronary syndrome, end stage renal failure systemic inflammatory disease, malignant disease, aldosterone antagonist user

Results Non-Spasm Spasm P-value Number 264 144 Age y.o. 67.1±13.9 67.8±1.1.1571 Gender M/F 116/148 97/47 <.1 Height cm 159.2±9.5 161.9±9.9.57 Weight kg 58.6±35.3 62.1±13.4.5945 BMI kg/m2 23.±19. 23.5±3.7.448 Hypertension % 53.8 68.8.77 Diabetes % 17.1 19.3.685 Dyslipidemia % 31.8 4..26 Hyperuremia % 14.4 27.1.18 Smoker % 3.3 53.5.9 Brinkman index 233.5±933.9 555.8±736.9 <.1

Results Non-Spasm Spasm P-value SBP mmhg 131.5±21.1 126.9±18.8.217 DBP mmhg 75.9±12.6 72.2±14.8.42 PP mmhg 55.3±15.2 54.4±13.3.546 HR /min 72.4±12.8 73.3±12.1.7657 EF % 75.2±7.46 7.1±11.2 <.1

Results Non-Spasm Spasm P-value BNP pg/ml 34.7±57.4 91.5±147.9. <.1 Aldosterone pg/ml 19.5±59.6 142.8±68.9 <.1 Renin activity ng/ml/hr 3.3±11.7 5.3±8.8.321 WBC /mm 3 57.8±1453.4 6175.5±942.2.2 Neutrophil /mm3 3382.±1117.7 3796.1±861.1.1 Lymphocyte /mm3 1838.7±111.4 18.1±555.8.5465 Fibrinogen mg/dl 292.7±78.3 34.7±59.1.752 CRP mg/l.93±1.2 1.45±.95 <.1

Results Non-Spasm Spasm P-value Total-cholesterol mg/dl 199.7±33.8 187.8±36.6.11 Trigriceride mg/dl 139.3±89.6 15.7±156.1.2838 HDL-cholesterol mg/dl 54.6±15.4 5.1±17.8.4 Uric Acid mg/dl 5.5±5.3 5.8±1.5.1138 Blood sugar mg/dl 111.4±43.2 119.4±95.5.369 HbA1c % 5.5±.9 5.6±.7.514 BUN mg/dl 16.2±4.7 17.2±5.9.883 Creatinine mg/dl.8±.23.93±.62.94 egfr ml/min/1.73m 2 78.5±23.4 7.7±24.1.22 Na meq/l 14.4±2.5 141.1±2.7.7652 K meq/l 4.2±.4 4.2±.3.869 Cl meq/l 12.1±2.3 11.7±3.4.4439

%male 1 8 Gender BMI Smoking P =.12 kg/m 2 5 4 5 (Brinkman index ) n.s. P =.12 4 6 3 3 4 2 2 2 1 1 Non-spasm Spasm Non-spasm Spasm Non-spasm Spasm

BNP Aldosterone Renin pg/ml 16 pg/ml 8 ng/ml/hr 1 P =.17 P <.1 n.s. 8 4 5 Non-spasm Spasm Non-spasm Spasm Non-spasm Spasm

CRP Neutrophil Fibrinogen mg/l 1. /mm 3 16 mg/dl 1 P <.1 14 P <.1 8 n.s. 12 5. 1 8 6 6 4 4 2 2 Non-spasm Spasm Non-spasm Spasm Non-spasm Spasm

Non-spasm Spasm CRP (mg/l) 1. n = 264 CRP (mg/l) 1. n = 144 8. R =.4 P =.8466 8. R =.79 P <.1 6. 6. 4. 4. 2. 2. 1 2 3 4 5 6 1 2 3 4 5 6 Plasma Aldosterone (pg/ml) Plasma Aldosterone (pg/ml) y =.2x + 1.51; R 2 =.1525 y =.97x +.544; R2=.524

Spasm Neutrophil (/mm 3 ) 1 8 Fibrinogen (mg/dl) n = 12 1 n = 12 R =.391 R =.426 P <.1 8 P <.1 6 6 4 4 2 2 1 2 3 4 5 6 Plasma Aldosterone (pg/ml) 1 2 3 4 5 6 Plasma Aldosterone (pg/ml) y = 4.8831x + 3146.2; R 2 =.1528 2 y =.3546x + 255.16; R =.1812

Multivariate Analysis Odds ratio (95% CI) P-value Aldosterone 1.6 (1.2-1.1).19 CRP 1.291 (1.41-1.6).198 Neutrophil 1. (.999-1.).653 Smoker 1.75 (.993-2.928).529

Summary 1. Levels of aldosterone and CRP were significantly higher in the spasm group than in the non-spasm group 2. Patients with coronary vasospasm were likely to have high levels of white blood cell count and neutrophil count. 3. There is a positive correlation between aldosternoe and CRP in the spasm group. 4. Multivariate analysis showed that elevation of aldosterone and CRP level were independently associated with vasospasm.

RAA system Aldosterone Aldosterone Receptors in Vessels Non-RAA system Adipocyte ACTH Potassium Endothelin Deleterious Effects of Aldosterone in Artery Coronary spasm? Endothelial Dysfunction VSMC Hypercontraction Oxidative Stress Inflammatory Reaction Thrombotic Phenomena Vascular Fibrosis

Pathogenesis of vasospasm 1. Shear stress, Acetylcholine, Bradykinin, Serotonin, Histamine, Substance P 2. Endothelial dysfunction Endothlium-dependent vaso-relaxation factors =EDRF (NO), EDHF Endothlium-derived contracting factors (EDCF) =ET-1, Angiotensin II, PGH2, TXA2, Super oxide 3. Oxidative stress Aldosterone NADPH oxidase activation 4. Chronic low-grade vascular inflammation 5. Hyper contractility of vascular smooth muscle cell Rho/ROCK activity 6. Deficiency of magnesium (endgenous Ca antagonist) 7. Loss of estrogen

Limitations 1. Cause of elevated aldosterone 2. Role of cortisol 3. Expression of mineral corticoid receptor 4. Effect of mineral corticoid receptor blocker 5. Racial differences, Ethnic characteristics

Conclusions 1. The levels of aldosternoe and CRP which were strongly associated with vasospasm had positive interactions. 2. Our results suggested elevated aldosterone in conjunction with inflammatory reaction may be involved in the pathogenesis of coronary spasm.